Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT01503515 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01503515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01503515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
March 21, 2013
Completion date
September 30, 2021
Enrollment
292 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

fungal infection, hematopoietic and lymphoid cell neoplasm